letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12345678910111213...99100»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Metastatic Lobular Adenocarcinoma Presenting as Gastric Outlet Obstruction (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5565;    
    It is more difficult, as in this case, when the endoscopic biopsy serves as the first tissue diagnosis of the primary cancer in the absence of a previously known focal mass. Figure: Gastric outlet obstruction endoscopy findings
  • ||||||||||  letrozole / Generic mfg., pazopanib / Generic mfg.
    Biliary Blockade: Liver Hemangioendothelioma Causing Common Bile Duct and Common Hepatic Duct Obstructions (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3324;    
    Case Description/ 70 year old female past medical history significant for estrogen/progesterone receptor positive breast cancer subsequently treated with lumpectomy and letrozole post surgery...Initially managed with Y90 embolization to the right hepatic artery and pazopanib...C: Intracytoplasmic vacuoles demonstrating red blood cell extravastation and poorly vasoformitive epitheloid cells with intracytoplasmic vacuoles. D: CAMTA1 staining positivity confirming diagnosis of epitheloid hemangioendothelioma.
  • ||||||||||  Metastatic Breast Cancer Manifesting as Rectal Linitis Plastica Diagnosed With Endoscopic Ultrasound- Fine Needle Biopsy (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_863;    
    She was treated with a left simple mastectomy with lymph nodes resection, radiotherapy, chemotherapy with paclitaxel, doxorubicin and cyclophosphamide and subsequent letrozole with complete remission of her disease...She continues to follow up with Hematology-Oncology and she was started on capecitabine...Figure: Figure 1. Endoscopy showing rectal irregular, congested and erythematous mucosa.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal, IO biomarker:  Potential Exacerbation of Polycystic Ovary Syndrome by Saccharin Sodium Using a Letrozole Rat Model. (Pubmed Central) -  Aug 17, 2024   
    Thus, SS showed an escalation in testosterone, progesterone, estrogen, and LH/FSH ratio, insinuating a perturbation in endocrine regulation. It is found that there is an impact of taste receptor downstream signaling on ovarian steroidogenesis and apoptosis instigating pathophysiological milieu of PCOS.
  • ||||||||||  Eligard (leuprolide acetate) / Tolmar, Sanofi
    Trial completion date, Trial primary completion date:  OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) -  Aug 9, 2024   
    P3,  N=250, Recruiting, 
    The obtained findings validated that dysregulated insulin signaling in PCOS rats detrimentally affects cognitive function, which is halted by PTS, unveiling the potential of PTS as a novel therapy for PCOS and related cognitive deficits. Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
  • ||||||||||  BPI-1178 / Beta Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov) -  Aug 6, 2024   
    P1/2,  N=224, Recruiting, 
    HPLC analysis revealed the presence of phytochemicals such as chlorogenic acid, p-coumaric acid, gallic acid, and kaempferol...After PCOS induction, animals of the disease-induced group were divided into five groups: one group used as disease control (PCOS) group, one group on metformin (20 Trial completion date: Mar 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Lichen planopilaris induced by chemotherapy for breast cancer (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_3814;    
    Most chemotherapeutic agents cause temporary hair loss, yet several cases of chemotherapy-induced LPP have been reported in the literature, often in breast cancer patients. Despite its relatively rare occurrence, there is a need to inform the patients about the possible risk of permanent hair loss and in case of such complications, multidisciplinary support, including dermatological treatments, should be provided.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Male breast cancer masked with herpes zoster (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_3039;    
    Physicians should be aware of male breast cancer in male patients with a painless breast mass. It should be noted that additional inflammatory diseases may mask breast cancer nodules.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Ribociclib-Associated Vitiligo: A Rare Dermatological Side Effect of Cancer Therapy (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2015;    
    CDK4/6 inhibitors represent a promising therapeutic avenue for breast cancer patients, albeit with associated cutaneous adverse effects such as vitiligo-like lesions, as evidenced by limited cases in literature. Further studies are needed to explore the correlation between the occurrence of these adverse effects and the positive treatment response in patients.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial primary completion date:  GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) -  Aug 5, 2024   
    P=N/A,  N=90, Recruiting, 
    Further studies are needed to explore the correlation between the occurrence of these adverse effects and the positive treatment response in patients. Trial primary completion date: Mar 2024 --> Jul 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Verzenio (abemaciclib) / Eli Lilly
    Enrollment open, Mismatch repair, Metastases:  ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab (clinicaltrials.gov) -  Aug 1, 2024   
    P2,  N=76, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    IT'S NOT A ''MET!'': METACHRONOUS EYE CARCINOMA ON PREVIOUSLY METASTATIC BREAST CANCER (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2665;    
    Healthcare providers must monitor survivors of cancer for the potential development of MPM. Discussing follow-up plans and lifestyle modifications becomes essential to mitigate these risks and enhance the overall well-being of cancer survivors.
  • ||||||||||  Piqray (alpelisib) / Novartis, Ibrance (palbociclib) / Pfizer
    PI3K INHIBITOR-INDUCED HYPERGLYCEMIA (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1288;    
    Use of insulin rather than oral antidiabetic therapy can result in better glucose tolerance as observed. Optimization of insulin use timing, based on the timing of intake of Alpesilib is important as Alpesilib causes insulin resistance through the mechanism described above.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Palbociclib and Fulvestrant Combined Regimen Induced Prolonged Bone Metastasis Control of Stage IV HR+/HER2- Breast Cancer: A Case Report. (Pubmed Central) -  Jul 30, 2024   
    The patient was started on therapeutic doses of letrozole and zoledronic acid in conjunction with adjuvant radiotherapy...A decision was made to switch letrozole for tamoxifen which resulted in disease stability...Palbociclib and fulvestrant were started accordingly, yielding a remarkable metabolic response of all bone metastatic lesions (stable disease) after three months of the regimen initiation. The aforementioned stable disease status continued for approximately three years up to this point.
  • ||||||||||  letrozole / Generic mfg.
    Retrospective data, Journal:  Progestin-primed ovarian stimulation with letrozole using different doses of medroxyprogesterone acetate per day: a retrospective cohort study. (Pubmed Central) -  Jul 29, 2024   
    Following multivariable regression analysis, no disparities were found in embryo characteristics (number of oocytes retrieved, number of available embryos, number of high-quality embryos) or pregnancy outcomes (clinical pregnancy rate, cumulative live birth rate) among the three groups. Progestin-primed ovarian stimulation with letrozole using different dose of medroxyprogesterone acetate per day was comparable in terms of the number of oocytes retrieved, the number of high-quality embryos, clinical pregnancy rate and cumulative live birth rate after frozen embryo transfer.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal:  Cytoarchitectural differences in reproductive organs of some polycystic ovary-like induced animal models. (Pubmed Central) -  Jul 28, 2024   
    Each of the subgroups also had a comparison control group. Following the completion of administration, the Wistar rats were euthanized, and their ovaries and uterus were collected for histological analysis.Increased proliferation of ovarian follicles was noted in the treated groups compared to control, as well as thickening of the endometrial layer.